Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 488

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 19
Chunk 488
---
 ​     -100%          ​               100%   ​               100%
Galapagos Biopharma Sweden AB                                          ​   Sweden            ​               0%   ​     -100%          ​               100%   ​               100%
Galapagos Biopharma Norway AS                                          ​   Norway            ​               0%   ​     -100%          ​               100%   ​               100%
Galapagos Biopharma Finland Oy                                         ​   Finland           ​               0%   ​     -100%          ​               100%   ​               100%
Galapagos Biopharma Denmark ApS                                        ​   Denmark           ​               0%   ​     -100%          ​               100%   ​               100%
Galapagos Biopharma Austria GmbH                                       ​   Austria           ​               0%   ​     -100%          ​               100%   ​               100%
Galapagos Biopharma Ireland Ltd                                        ​   Ireland           ​               0%   ​     -100%          ​               100%   ​               100%
Galapagos Biotech Ltd (formerly Inpharmatica Ltd.)                     ​   United Kingdom    ​               0%   ​     -100%          ​               100%   ​               100%
​
There are no significant restrictions on the group’s ability to access or use assets and settle liabilities of one of the group’s subsidiaries.​
In December 2024, we signed a share purchase agreement regarding the shares of Galapagos Real Estate Belgium BV. We expect closing of this transaction to occur by March 31, 2025.​
On January 7, 2025, we incorporated Galapagos (Shanghai) Bioscience Co., Ltd., in the People’s Republic of China, and on February 14, 2025 we incorporated XYZ SpinCo NV.
​
35. Financial risk managementFinancial risk factorsOur financial risks are managed centrally. Our finance department coordinates the access to national and international financial markets and considers and manages continuously the financial risks concerning our activities. These relate to the following financial markets risks: credit risk, liquidity risk, currency risk and interest rate risk. Our interest rate risk is limited because we have no financial debt. In case of decreasing interest rates we will face a reinvestment risk on our strong cash and cash equivalents and financial investments balance. We do not buy or trade financial instruments for speculative purposes